[36-38]It has been proved that μ-opioid receptor agonists transactivate pro-oncogenic vascular endothelial growth factors (VEGF) and epidermal growth factor (EGF) receptors resulting in enhanced tumour growth (reversed by opioid receptor antagonism). The gene discussed is VEGFA; the disease is neoplasm.